MedPath

To determine radiation dermatitis severity reduction by prophylactic dressing in breast cancer patients who are receiving whole breast irradiation.

Not Applicable
Conditions
Health Condition 1: C50- Malignant neoplasm of breast
Registration Number
CTRI/2022/08/044659
Lead Sponsor
JIPMER
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Above 18 years of age

2. Breast-conservative surgery for breast cancer

3. A hypofractionation regimen of 40.5Gy in 15

fractions with simultaneous integrated boost

technique.

Exclusion Criteria

1. Active smoking status

2. Metastatic disease

3. Previous radiation to the ipsilateral breast

4. Flap reconstruction surgery

5. Active dermatitis

6. Any preexisting dermatological disorders

7. Treatment with topical or oral corticosteroids8. Mastectomy

9. Tattoos in the irradiation area

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To determine the reduction in radiation dermatitis severity using CTCAE v.5 criteria, modified RISRAS and modified <br/ ><br>10-point Catterall skin scoring profile for early <br/ ><br>breast cancer patients undergoing hypofractionated simultaneous integrated boost using VMAT by prophylactic polyurethane film dressing.Timepoint: At the last fraction of radiation and 4 weeks post radiation
Secondary Outcome Measures
NameTimeMethod
To assess the impact of skin disease on the quality of life using Dermatology Life Quality Index (DLQI) questionnaire.Timepoint: At the last fraction of radiation and 4 weeks post radiation
© Copyright 2025. All Rights Reserved by MedPath